Alemtuzumab induction in pediatric kidney transplantation

Pediatric Transplantation

Volumn 17, Issue 2, 2013, Pages 168-178

  Kaabak, Michael M ^a   Babenko, Nadezda N ^a   Samsonov, Dmitry V ^b   Sandrikov, Valery A ^b   Maschan, Alexey A ^a,c   Zokoev, Alan K ^a  

^a PETROVSKY NATIONAL RESEARCH CENTER OF SURGERY   (Russian Federation)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Oncology and Immunology   (Russian Federation)

Author keywords

alemtuzumab; induction therapy; pediatric kidney transplantation; steroid free immunosupression

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; BK VIRUS INFECTION; CHILD; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PEDIATRIC SURGERY; PNEUMONIA; POSTOPERATIVE PERIOD; PREMEDICATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL; TIME;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84874453596     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/petr.12048     Document Type: Article

References (24)

1. Flynn JM, Byrd JC,. Alemtuzumab monoclonal antibody therapy. Curr Opin Oncol 2000: 12: 574-581.
2. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW,. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003: 101: 1422-1429. (Pubitemid 36182516)
3. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003: 76: 120-129. (Pubitemid 36877125)
4. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1998: 2: 1394-1399.
5. Kirsch BM, Haidinger M, Zeyda M, et al. Alemtuzumab (Campath-IH) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006: 16: 254-257. (Pubitemid 44809916)
6. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998: 351: 1701.
7. Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-Efficacy and safety at five years. Am J Transplant 2005: 5: 1347-1353. (Pubitemid 40839424)
8. Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009: 9: 355-366.
9. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011: 364: 1909-1919.
10. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: Alemtuzumab induction with tacrolimus monotherapy-An open label, randomized trial. Transplantation 2011: 92: 774-780.
11. Calne R, Watson CJE,. Some observations in prope tolerance. Curr Opin Organ Transplant 2011: 16: 353-358.
12. Bartosh SM, Knechtlen SJ, Sollinger HW,. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005: 5: 1569-1573. (Pubitemid 40839455)
13. Shapiro R, Ellis D, Tan HP, et al. Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr 2006: 148: 813-818. (Pubitemid 43870082)
14. Tan HP, Donaldson J, Ellis D, et al. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation 2008: 86: 1725-1731.
15. Barratt-Boyesa SM, Thomson AW,. Dendritic cells: Tools and targets for transplant tolerance. Am J Transplant 2005: 5: 2807-2813. (Pubitemid 43923940)
16. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005: 353: 770-781. (Pubitemid 41215486)
17. Gaspari F, Anedda MF, Signorini O, et al. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol 1997: 8: 647-652.
18. Momynaliev KT, Gorbatenko EV, Shevtsov AB, Gribanov OG, Babenko NN, Kaabak MM,. Prevalence and subtypes of BK virus in pediatric renal transplant recipients in Russia. Pediatr Transplant 2012: 16: 151-159.
19. NAPRTCS. Annual Transplant Report, 2010. Available at: https://web.emmes.com/study/ped/annlrept/2010-Report.pdfhttps://web.emmes.com/ study/ped/annlrept/annlrept.html (accessed April 26, 2012).
20. Nankivell BJ, Borrows RJ, Chir B, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003: 349: 2326-2333. (Pubitemid 37509740)
21. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713-723. (Pubitemid 29082898)
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008: 8: 753-760. (Pubitemid 351347767)
23. Van Der Mast BJ, Rischen-Vos J, De Kuiper P, Vaessen LM, Van Besouw NM, Weimar W,. Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency. Transplantation 2005: 80: 1220-1225. (Pubitemid 41746800)
24. Van De Wetering J, Koumoutsakos P, Peeters A, et al. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation. Clin Transplant 2011: 25: 40-46.